{'fraction_non_alphanumeric': 0.036585365853658534, 'fraction_numerical': 0.01869918699186992, 'mean_word_length': 5.478947368421053, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles.

AIM:To prepare valaciclovir polybutylcyan_oacrylate nanoparticles (VACV-PBCA-NP) with liver targeting and hepatocyte permeable charateristics.METHODS: Emulsion polymerization method was employed to prepare VACV-PBCA-NP.The formula and preparation conditions were optimized by using the uniform design. The organ distribution of the intravenously injected VACV-PBCA-NP and VACV in animal was determined using HPLC. The hepatocytes permeability of VACV-PBCA-NP was demonstrated by cell uptake experiment in vitro.RESULTS:The drug loading and the drug embedding ratio of VACV-PBCA-NP were 11.20% and 84.85% respectively, with an average diameter of 104.77nm ±11.78nm. The releasing characteristics in vitro fitted the two-phase kinetics. 74.49% of the drug was found to localize in the liver 15min after the administration of VACV-PBCA-NP in the mice. Compared with VACV, VACV-PBCA-NP showed distinct characteristic of sustainedrelease in vivo and the drug entering hepatocytes were also greatly increased.CONCLUSION:VACV-PBCA-NP has the char_acteristic of liver targeting and can increase the permeability of VACV to hepatocytes.